Insider · CIK 0001393207
Brian Corvese
Files at PTIX (Protagenic Therapeutics, Inc.\new), AGEN (AGENUS INC), INKT (MiNK Therapeutics, Inc.). First filing -, latest -.
In brief
Brian Corvese files SEC Form 4 as director at PTIX (Protagenic Therapeutics, Inc.\new), and also at AGEN (AGENUS INC), INKT (MiNK Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Brian Corvese has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 17 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | INKT MiNK Therapeutics, Inc. | AGrant or award Common Stock | +1,633 | $10.95 | $18k | 54,770 | 41 d ago |
| Aug 5, 2026 | AGEN AGENUS INC | AGrant or award Stock Optionderivative | +100,000 | $0.00 | $0 | 100,000 | Aug 11, 2026 |
| Mar 2, 2026 | INKT MiNK Therapeutics, Inc. | AGrant or award Common Stock | +1,640 | $10.90 | $18k | 51,693 | Jun 2, 2026 |
| Jun 1, 2026 | INKT MiNK Therapeutics, Inc. | AGrant or award Common Stock | +1,444 | $12.38 | $18k | 53,137 | Jun 2, 2026 |
| Apr 24, 2026 | AGEN AGENUS INC | AGrant or award Stock Optionderivative | +210,000 | $0.00 | $0 | 210,000 | Apr 28, 2026 |
| Jan 2, 2026 | INKT MiNK Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +5,395 | $0.00 | $0 | 5,395 | Jan 6, 2026 |
| Dec 1, 2025 | INKT MiNK Therapeutics, Inc. | AGrant or award Common Stock | +1,612 | $11.09 | $18k | 50,053 | Dec 3, 2025 |
| Sep 9, 2025 | INKT MiNK Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +3,225 | $0.00 | $0 | 3,225 | Sep 11, 2025 |
| Sep 2, 2025 | INKT MiNK Therapeutics, Inc. | AGrant or award Common Stock | +1,290 | $13.86 | $18k | 48,441 | Sep 3, 2025 |
| Jun 17, 2025 | AGEN AGENUS INC | AGrant or award Stock Optionderivative | +750 | $0.00 | $0 | 750 | Jun 20, 2025 |
| Jun 17, 2025 | AGEN AGENUS INC | AGrant or award Stock Optionderivative | +30,000 | $0.00 | $0 | 30,000 | Jun 20, 2025 |
| Jun 2, 2025 | INKT MiNK Therapeutics, Inc. | AGrant or award Common Stock | +2,494 | $7.17 | $18k | 47,151 | Jun 4, 2025 |
| Mar 3, 2025 | INKT MiNK Therapeutics, Inc. | AGrant or award Common Stock | +2,033 | $8.79 | $18k | 44,657 | Mar 5, 2025 |
| Dec 1, 2024 | INKT MiNK Therapeutics, Inc. | AGrant or award Common Stock | +24,400 | $0.73 | $18k | 426,283 | Dec 3, 2024 |
| Mar 25, 2024 | PTIX Protagenic Therapeutics, Inc.\new | AGrant or award PTIX Common stock Optionsderivative | +43,750 | $1.74 | $76k | 43,750 | Mar 29, 2024 |
| Mar 1, 2024 | INKT MiNK Therapeutics, Inc. | AGrant or award Common Stock | +18,816 | $0.95 | $18k | 365,527 | Mar 5, 2024 |
| Dec 1, 2023 | INKT MiNK Therapeutics, Inc. | AGrant or award Common Stock | +17,188 | $1.04 | $18k | 346,711 | Dec 5, 2023 |
Questions about Brian Corvese
Answered from the filings on this page, as of the latest one.
Is Brian Corvese buying or selling?
Brian Corvese has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Brian Corvese's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Brian Corvese has 0.
Where does Brian Corvese file Form 4?
Brian Corvese has filed Form 4 at PTIX (Protagenic Therapeutics, Inc.\new); AGEN (AGENUS INC); INKT (MiNK Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.